Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia
1. 系统已在2025-11-06 17:03:37对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1126/scitranslmed.abq3010
文献链接: https://www.science.org/doi/10.1126/scitranslmed.abq3010
其他信息:
出版社: American Association for the Advancement of Science (AAAS)
作者: Giorgio Ottaviano; Christos Georgiadis; Soragia Athina Gkazi; Farhatullah Syed; Hong Zhan; Annie Etuk; Roland Preece; Jan Chu; Agnieszka Kubat; Stuart Adams; Paul Veys; Ajay Vora; Kanchan Rao; Waseem Qasim; undefined undefined; Jesmina James; Kimberly Gilmour; Sarah Inglott; Rebecca Thomas; Lana Mhaldien; Attia Hasnain; Natalia Izotova; Nina Tailor; Barry Flutter; Batoul Ahmed; Toni Braybrook; Danielle Pinner; Lindsey Williams; Ka-Yuk Ko; Anna Taylor; Adebimpe Eshilokun; Susan Staddon; Persis Amrolia; Robert Chiesa; Giovanna Lucchini; Arina Lazareva; Khushnuma Mullanfiroze; Annette Hill; Maria Finch; Rachel Mead; Lindsey Young; Christopher Abbott; Philip Ancliff; Sara Ghorashian; Sujith Samarasinghe; Anupama Rao; Jack Bartram; Vesna Pavasovic; Danny Cheng; Ayad Eddaoudi; Farzin Farzaneh; Sabine Domning; Rene Heimke; Richard Gabriel; Martin Sauer; Rita Beier; Kirste Madeleine; Cornelia Eckert; Marco Willem Schilham; Anja Magdalena Jansen-Hoogendijk; Jin Soo Kim; Daesik Kim
